Cumberland Pharmaceuticals Stock Income Statements

Cumberland Pharmaceuticals Quarterly Income Statements Chart

Quarterly

Annual

Revenue

Gross Profit

Operating Profit

Net Income

Cumberland Pharmaceuticals Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31
revenue	9,353,066	10,085,926	10,888,877	9,224,638	9,123,680	11,413,072	10,299,152	11,175,045	8,319,861	8,072,540	9,055,483	10,537,159	10,261,534	9,250,689	9,598,177	8,330,734	13,678,372	10,371,918	11,580,600	11,902,747	13,497,906	8,492,530	10,163,724	8,587,605	11,649,288	11,196,961	8,667,127	9,636,755	9,081,440	8,791,753	7,414,835	7,737,532	8,037,488	7,885,048	8,909,741	8,686,774	9,329,412	9,729,047	9,750,168	8,093,244	8,159,667	6,528,575	7,081,088	10,258,132	13,696,366	12,531,719	12,366,940	10,256,212	13,031,830	13,054,278	14,389,741	10,666,927	12,814,914	12,190,870	10,739,935	10,130,652	10,714,306	13,597,760	9,820,613	9,404,599	9,811,092	8,602,709	8,357,532	8,303,827	7,433,832	7,338,604	7,384,368	5,906,785	6,050,590	5,758,635	4,618,501	1,387,754
cost of revenue	2,725,296	1,765,590	1,520,774	1,250,264	2,650,309	2,224,443	2,031,884	2,211,885	3,325,243	1,328,027	1,740,649	2,417,329	2,266,018	2,142,839	2,609,982	1,634,181	2,818,213	1,921,875	2,012,196	1,999,736	2,866,352	1,460,463	1,523,319	1,527,961	2,153,809	2,166,353	1,668,926	1,381,497	1,605,512	1,973,948	1,155,261	1,223,939	1,589,152	980,176	1,237,001	1,161,841	1,360,909	1,339,723	1,298,816	1,053,717	2,145,011	1,030,943	1,154,833	1,108,635	2,172,762	921,862	1,103,005	848,550	1,951,200	1,341,256	1,283,160	786,938	954,199	909,434	863,725	859,288	865,178	1,761,069	777,076	733,218	817,459	735,492	737,230	755,491	759,510	688,904	650,122	571,092	946,249	764,704	661,017	27,163
gross profit	6,627,770	8,320,336	9,368,103	7,974,374	6,473,371	9,188,629	8,267,268	8,963,160	4,994,618	6,744,513	7,314,834	8,119,830	7,995,516	7,107,850	6,988,195	6,696,553	10,860,159	8,450,043	9,568,404	9,903,011	10,631,554	7,032,067	8,640,405	7,059,644	9,495,479	9,030,608	6,998,201	8,255,258	7,475,928	6,817,805	6,259,574	6,513,593	6,448,336	6,904,872	7,672,740	7,524,933	7,968,503	8,389,324	8,451,352	7,039,527	6,014,656	5,497,632	5,926,255	9,149,497	11,523,604	11,609,857	11,263,935	9,407,662	11,080,630	11,713,022	13,106,581	9,879,989	11,860,715	11,281,436	9,876,210	9,271,364	9,849,128	11,836,691	9,043,537	8,671,381	8,993,633	7,867,217	7,620,302	7,548,336	6,674,322	6,649,700	6,734,246	5,335,693	5,104,341	4,993,931	3,957,484	1,360,591
operating expenses
research and development	1,264,753	1,924,768	1,145,038	1,499,670	1,405,841	1,714,254	1,823,693	1,745,136	1,612,827	1,453,873	1,360,398	1,257,367	1,399,433	1,230,335	1,421,502	1,722,555	2,079,782	1,278,013	1,458,366	1,267,601	2,689,413	1,306,055	1,450,390	1,874,939	979,414	943,162	1,080,426	898,363	1,160,786	644,662	678,780	706,472	403,127	757,442	828,070	1,859,012	767,109	934,783	861,154	826,373	1,339,295	1,440,584	1,386,904	1,448,718	441,215	1,696,592	1,553,343	1,404,022	1,758,326	1,233,025	1,027,048	1,009,673	1,379,862	1,138,955	1,034,800	773,868	951,559	640,877	2,630,725	770,117	1,670,022	730,640	918,460	1,109,942	1,136,038	1,016,835	1,088,845	452,199	270,988	521,087	851,960	588,949
sales and marketing	4,759,230	4,743,142	4,672,075	4,277,318	3,379,434	4,110,397	4,556,685	4,614,429	3,305,979	3,800,288	4,121,817	3,787,340	3,604,541	3,587,842	3,865,406	3,707,676	5,592,963	5,562,443	5,153,129	5,120,505	5,708,434	4,803,112	5,076,250	4,670,511	5,318,546	6,226,438	4,654,933	5,293,020	3,967,526	3,614,714	3,272,279	3,698,962	3,349,539	3,608,828	3,505,486	3,530,915	3,536,236	3,821,953	3,930,082	3,613,931	3,761,552	3,410,205	3,542,049	3,673,939	4,942,425	4,914,551	5,491,964	4,980,553	4,686,486	5,060,546	5,904,444	5,288,584	5,526,822	5,692,048	5,848,123	5,607,512	5,582,278	6,087,807	4,383,802	4,140,187	3,758,108	3,620,243	3,644,796	3,364,006	2,672,062	2,508,213	2,456,027	2,417,053	2,525,100	1,931,543	1,565,921	1,325,976
general and administrative
total operating expenses	3,439,184	2,343,855	2,369,883	2,498,993	3,507,678	2,166,118	2,203,975	2,302,349	3,412,588	2,039,799	2,097,130	2,230,509	3,587,977	2,381,273	2,190,764	2,036,284	3,135,405	2,422,886	2,528,916	2,670,056	3,673,387	2,067,981	2,334,223	2,330,281	3,476,212	2,090,785	2,353,140	2,110,233	2,743,868	1,865,575	1,874,396	2,077,972	2,015,606	1,794,279	2,153,562	1,644,141	2,206,037	2,158,057	2,140,249	1,897,217	3,100,407	1,958,629	1,855,201	2,575,739	2,765,056	1,901,986	2,164,098	2,265,025	2,755,816	2,117,684	2,344,064	1,980,391	2,519,210	1,806,975	1,782,834	1,881,203	2,424,145	2,537,627	1,236,435	1,444,863	1,867,517	1,167,687	1,021,639	1,083,094	1,344,572	827,279	946,962	1,019,129	1,162,178	652,234	565,017	619,918
operating income	8,715,940	10,186,939	9,345,244	9,506,052	8,751,175	9,477,217	10,113,806	10,255,159	9,348,614	8,307,908	8,750,563	8,444,130	9,741,462	8,316,536	8,569,157	8,542,554	11,857,568	10,297,128	10,170,119	10,079,807	12,894,243	8,838,950	9,509,383	9,511,866	10,398,805	9,869,957	8,679,072	8,913,060	8,433,299	6,687,673	6,364,883	7,014,176	6,285,657	6,633,988	6,998,809	7,520,817	7,022,365	7,400,286	7,235,743	6,631,476	8,486,733	7,012,400	7,066,799	7,823,446	8,270,611	8,630,694	9,324,004	8,761,647	9,260,015	8,614,662	9,474,724	8,471,988	9,514,338	8,837,579	8,866,350	8,460,856	9,236,484	9,464,632	8,449,421	6,554,356	7,493,947	5,716,709	5,781,814	5,754,797	5,341,994	4,550,458	4,691,105	4,085,086	4,152,759	3,299,078	3,177,069	2,563,579
net income	-2,088,169	-1,866,603	22,859	365,577	-2,277,804	-266,986	-1,846,538	-1,275,958	-4,353,996	-1,563,395	-1,435,729	-324,300	-1,745,946	-1,208,686	-1,580,962	-1,846,001	-997,409	-1,847,085	-601,715	-176,796	-2,262,689	-1,806,883	-868,978	-2,452,222	-903,326	-839,349	-1,680,871	-657,802	-957,371	130,132	-105,309	-500,583	-162,679	270,884	673,931	4,116	946,138	989,038	1,215,609	408,051	-2,472,077	-1,514,768	-1,140,544	1,326,051	3,252,993	2,979,163	1,939,931	646,015	1,711,269	3,098,360	3,631,857	1,408,001	2,237,522	2,443,857	1,009,860	810,508	693,435	2,372,059	594,116	2,117,025	1,499,686	2,150,508	1,838,488	1,793,539	1,332,328	2,099,242	2,043,141	1,250,607	951,582	1,694,853	780,415	-1,202,988

We provide you with 20 years income statements for Cumberland Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Cumberland Pharmaceuticals stock. Explore the full financial landscape of Cumberland Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Cumberland Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.